DBV re­struc­tur­ing claims 200 jobs as it beats out a path to­ward peanut patch OK

Reg­u­la­to­ry trou­bles around its peanut al­ler­gy treat­ment have hurt DBV Tech­nolo­gies bad.

It be­came even clear­er Thurs­day morn­ing as the French biotech dis­closed the scope of a glob­al re­struc­tur­ing it an­nounced back in June. More than 200 jobs are be­ing cut, leav­ing a team of 90 to car­ry on with the hard task of scor­ing ap­proval for its Vi­askin Peanut patch.

With a for­mal go-ahead from au­thor­i­ties in France, CEO Daniel Tassé ex­pects the mea­sures to re­duce av­er­age month­ly cash burn by up to half, there­by keep­ing the com­pa­ny afloat un­til late 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER